Why the study?
Does doxazosin reduce blood pressure without decreasing calf flow in uncomplicated hypertensive patients?
Does doxazosin reduce blood pressure without decreasing calf flow in uncomplicated hypertensive patients?
Doxazosin effectively lowers blood pressure without compromising calf blood flow, suggesting its utility in hypertensive patients with peripheral artery disease.
Answers are grounded in this paper and cite their sources.
Doxazosin may lower BP without reducing calf flow in hypertension; hypothesis-generating for PAD, should not yet change practice.
In the treatment of hypertensive patients with peripheral vascular disease, alpha 1-adrenoceptor blockers may be considered first-choice drugs since they reduce the total peripheral resistance and do not decrease the plasma volume. As a preliminary step, we investigated the plethysmographic effects of doxazosin (1-8 mg for 6 weeks) on calf flow in 32 uncomplicated hypertensive patients. Despite the fall in sitting and standing blood pressure (from 163 +/- 18/101 +/- 6 to 147 +/- 19/94 +/- 8 mmHg and from 162 +/- 18/107 +/- 9 to 145 +/- 18/95 +/- 8 mmHg, respectively; both P less than 0.001) the calf flow was not decreased at rest and after ischaemia. Resting resistance was not significantly reduced (from 49.5 +/- 35 to 38.9 +/- 33 mmHg/100 ml per min) but its fall was significantly correlated with the fall in mean blood pressure (rs = 0.35, P less than 0.05). These findings confirm that doxazosin may be useful in the treatment of hypertension complicated by peripheral artery disease.
No takes yet. Share an insight, caveat, or question.
Mozzato et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: